

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 66808

Title: Hepatitis B: Who should be treated? Managing patients with chronic hepatitis B

during the immune-tolerant and immunoactive phases

Reviewer's code: 03544596 Position: Editorial Board Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: Turkey

Author's Country/Territory: Japan

Manuscript submission date: 2021-04-23

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-01 07:09

Reviewer performed review: 2021-05-10 07:21

Review time: 9 Days

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Thanks to thr authors for this good-organised review. The manuscript interprets the findings adequately and appropriately but information and literature in children is low. If the authors give more information about hepatitis B infection in children, with latest literature, the article would be better.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 66808

Title: Hepatitis B: Who should be treated? Managing patients with chronic hepatitis B

during the immune-tolerant and immunoactive phases

Reviewer's code: 05533129 Position: Peer Reviewer

Academic degree: MBChB, MD, MS

Professional title: Doctor, Staff Physician

Reviewer's Country/Territory: Sweden

Author's Country/Territory: Japan

Manuscript submission date: 2021-04-23

Reviewer chosen by: Man Liu

Reviewer accepted review: 2021-05-21 05:10

Reviewer performed review: 2021-06-16 03:04

Review time: 25 Days and 21 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

I read with interest the review performed by Kawanaka M et al, in which a comparison across major guidelines for the treatment of chronic HBV mono-infection in the immunotolerant and immune-active phases. Overall, the review is well-written with clear presentation of different management across the guidelines. Few comments, though: • Has the author considered writing a paragraph on HBV coinfection treatment with other viral hepatides such as HCV and HDV? Minor spelling errors: •

Page 3—line 21 remove (,) after 2% • Page 6 – line 7 morality -> mortality

Line 8 put article before quality

Line 15 -> consider sex instead of gender •

Page 12 – line 21 -> correct Tenofovir